CARDIOVASCULAR COMPLICATIONS OF ANTICANCER THERAPY: CLINICAL FEATURES, DIAGNOSIS, TREATMENT, PREVENTION (PART II)


如何引用文章

全文:

详细

The given review is devoted to the problem of the cardiotoxicity of chemotherapeutic agents. Many of chemotherapeutic agents can cause cardiovascular complications such as left ventricular dysfunction and heart failure development, myocardial ischemia, arterial hypertension, thromboembolism, QT prolongation and arrhythmias. The toxic influence of the most often used chemotherapeutic agents on heart (such as antimetabolites, alkylating agents, platinum compounds, taxanes, vinca alkaloids, monoclonal antibodies, anthracycline antibiotics, topoisomerase and protein kinase inhibitors, immunomodulatory agents and cytokines) has been described. The results of recent studies on etiology, pathogenesis and clinical features of chemotherapy-induced cardiotoxicity were present in the first part of review. The clinical features, diagnosis, treatment and prevention of the cardiotoxicity of chemotherapeutic agents, are described in the second part of the review

作者简介

N. Vatutin

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine; Donetsk, 83045, Ukraine

E. Sklyannaya

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine; Donetsk, 83045, Ukraine

Mariam El-Khatib

M. Gorky Donetsk National Medical University

Email: el-khatib.mariam@yandex.ru
MD, Assistant Professor of the Department of Hospital Therapy; Donetsk, 83003,Ukraine Donetsk, 83003, Ukraine

G. Taradin

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine; Donetsk, 83045, Ukraine

参考

  1. Zamorano J.L., Lancellotti P., Muñoz D.R. et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 2016; 37(36): 2768-801. doi: 10.1093/eurheartj/ehw211
  2. Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии. Сердце: журнал для практикующих врачей. 2016; 15(1): 50-7. doi: 10.18087/rhj.2016.1.2115
  3. Cardinale D., Colombo A., Colombo N. Acute coronary syndrome induced by oral capecitabine. Can. J. Cardiol. 2006; 22(3): 251-3.
  4. Ewer M.S., O’Shaughnessy J.A. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin. Breast Cancer. 2007; 7(8): 600-7.
  5. Матяш М.Г., Кравчук Т.Л., Высоцкая В.В., Чернов В.И., Гольдберг В.Е. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский онкологический журнал. 2008; 6: 66-75.
  6. Калинкина Н.В. Повреждение сердца антрациклинами. Донецк: Каштан; 2008.
  7. Curigliano G., Cardinale D., Suter T., Plataniotis G., de Azambuja E., Sandri M.T., et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann. Oncol. 2012; 23(Suppl 7): vii155-66:155-66. doi: 10.1093/annonc/mds293.
  8. Manrique С.R., Park M., Tiwari N., Plana J.C., Garcia MJ. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin. Med. Insights. Cardiol. 2017; 11: 1-12. doi: 10.1177/1179546817697
  9. Sarkiss M.G., Yusuf S.W., Warneke C.L., Botz G., Lakkis N., Hirch-Ginsburg C., et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007; 109(3): 621-7. doi: 10.1002/cncr.22434.
  10. Крикунова О.В., Васюк Ю.А., Висков Р.В., Крикунов П.В., Иванова С.В., Коник В.А. Сердечные тропонины в выявлении кардиотоксичности у пациентов, подвергающихся химиотерапии. Российский кардиологический журнал. 2015; 12: 119-25. http://dx.doi.org/10.15829/1560-4071-2015-12-119-125.
  11. Снеговой А. В., Виценя М. В., Копп М. В., Ларионова В. Б. Практические рекомендации по коррекции кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. Злокачественные опухоли. 2015; 4: 369-78.
  12. Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug. Saf. 2000; 22(4): 263-302.
  13. Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2008; 51(2): 210-47.
  14. Lipshultz S.E., Franco V.I., Miller T.L., Colan S.D., Sallan S.E. Cardiovascular disease in adult survivors of childhood cancer. Annu. Rev. Med. 2015; 66: 161-76. doi: 10.1146/annurev-med-070213-054849.
  15. Pande A., Lombardo J., Spangenthal E., Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007; 27(5B): 3465-70.
  16. Chobanian A.V., Bakris G.L., Black H.R., Green L.A., Izzo J.L. Jr, Jones D.W. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6): 1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2.
  17. Rixe O., Billemont B., Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann. Oncol. 2007; 18(6): 1117.
  18. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(Suppl.6): 454S-545S. doi: 10.1378/chest.08-0658.
  19. Gupta A., Lawrence A.T., Krishnan K., Kavinsky C.J., Trohman R.G. Current concepts in the mechanisms and management of druginduced QT prolongation and torsade de pointes. Am. Heart J. 2007; 153(6): 891-9. doi: 10.1016/j.ahj.2007.01.040.
  20. Palumbo A., Rajkumar S.V., Dimopoulos M.A., Richardson P.G., San Miguel J., Barlogie B., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(2): 414-23. doi: 10.1038/sj.leu.2405062.
  21. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 2009; 53(24): 2231-47. doi: 10.1016/j.jacc.2009.02.050.
  22. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosinekinase inhibitor sunitinib. Lancet. 2007; 370(9604): 2011-9. doi: 10.1016/S0140-6736(07)61865-0.
  23. Palumbo A., Rajkumar S.V., Dimopoulos M.A., Richardson P.G., San Miguel J., Barlogie B., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(2): 414-23. doi: 10.1038/sj.leu.2405062.
  24. Senkus E., Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 2011; 37(4): 300-11. doi: 10.1016/j.ctrv.2010.11.001.
  25. Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109(25): 3122-31. doi: 10.1161/01.CIR.0000133187.74800.B9.
  26. Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. Eur. Heart J. 2013; 34 (15): 1102-11. doi: 10.1093/eurheartj/ehs181.
  27. Гендлин Г.Е., Емелина Е.И., Никитин И.Г., Васюк Ю.А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал 2017; 3: 145-54. doi: 10.15829/1560-4071-2017-3-145-154
  28. Ewer M.S., Swain S.M., Cardinale D., Fadol A., Suter T.M. Cardiac dysfunction after cancer treatment. Tex. Heart Inst. J. 2011; 38(3): 248-52.
  29. Hrdina R., Gersl V., Klimtova I., Simunek T., Machackova J., Adamcova M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove). 2000; 43(3): 75-82.
  30. Miolo G.M., La Mura N., Nigri P., Murrone A., Da Ronch L., Viel E. et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol Oncol. 2006; 40(3): 149-61.

版权所有 © Eco-Vector, 2018


 


##common.cookie##